Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cambridge Heart, Inc.
Microvolt T-wave alternans tested in non-ischemic patient population
December 7th, 2004
Cambridge Heart, Inc., (OTCBB:CAMH) presented positive scientific evidence at the annual American Heart Association meeting that demonstrates the efficacy of Microvolt T-wave alternans (MTWA) testing among a non-ischemic study population. The current data complements results of a study among ischemic patients published last month in Circulation. Both studies show T-Wave Alternans testing to be highly efficacious in identifying which heart patients are at negligible risk of sudden death and may therefore be able to avoid ICD implantation "[The] results reaffirm information presented in previously published studies. We have now demonstrated the...
Source: Cardiovascular Business Week (2004-12-07)
|
